View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) US Patent Office to Allow Key Patent for Progenza

🕔7/10/2018 9:01:37 AM 2602

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Progenza.

Read Full Article

Regeneus Ltd (ASX:RGS) Update on Licensing Progenza in Japan

🕔7/3/2018 10:00:36 AM 2167

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term. The company had disclosed that it anticipated completing the collaboration before the end of 30 June but discussions have taken longer than originally anticipated.

Read Full Article

Regeneus Ltd (ASX:RGS) Grant of ASX Waiver

🕔6/28/2018 11:40:34 AM 2465

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has entered into an R&D loan facility agreement with Paddington St Finance. The maximum loan value of the facility is the lesser of $2 million or 80% of the estimated refundable tax offset credits under the ATO's R&D tax incentive.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔4/26/2018 9:05:20 AM 2887

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly Report for the period ended 31 March, 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Trial Results of Progenza for Knee Osteoarthritis Published

🕔3/7/2018 10:55:47 AM 4469

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the previously reported positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis have been published in the Journal of Translational Medicine.

Read Full Article

Regeneus Ltd (ASX:RGS) 2018 Half-Year Results and Business Update

🕔2/20/2018 1:43:32 PM 3525

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Half-Year Report for the 6 months to 31 December 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Progenza Granted Advanced Therapy Medicinal Product Designation by European Medicines Agency

🕔2/14/2018 9:42:32 AM 4129

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Progenza has been granted an Advanced Therapy Medicinal Product classification by the Committee for Advanced Therapies of the European Medicines Agency, following consultation with the European Commission.

Read Full Article

Regeneus Ltd (ASX:RGS) Japanese Patent Office to Grant Patent for Cancer Vaccine Technology

🕔2/12/2018 9:48:27 AM 4890

Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Japanese Patent Office has issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.

Read Full Article

Regeneus Ltd (ASX:RGS) Announces Successful Results in Acne Study

🕔2/6/2018 10:45:05 AM 4220

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that topical use of Sygenus gel for 6 weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.

Read Full Article

Regeneus Ltd (ASX:RGS) Appoints Japan-Based Non-Executive Director with Extensive Pharmaceutical Industry Experience

🕔12/11/2017 9:59:39 AM 2884

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of Leo Lee as an independent non-executive director of Regeneus with effect from December.

Read Full Article
###

98,176 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 256) (Last 30 Days: 1193) (Since Published: 45655) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media